Immune-mediated thrombotic thrombocytopenic purpura
Clinical trials for Immune-mediated thrombotic thrombocytopenic purpura explained in plain language.
Never miss a new study
Get alerted when new Immune-mediated thrombotic thrombocytopenic purpura trials appear
Sign up with your email to follow new studies for Immune-mediated thrombotic thrombocytopenic purpura, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug could keep rare blood disease in check
Disease control Recruiting nowThis pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another …
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase 2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment
Disease control Recruiting nowThis study tests whether a simpler treatment for immune thrombotic thrombocytopenic purpura (iTTP) works as well as the standard approach. Instead of daily plasma exchange (an invasive procedure), patients receive plasma infusions, immune-suppressing drugs, and caplacizumab. The …
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC